Verrica Pharmaceuticals Inc.
VRCA
Positions held
Your positionsVRCA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $71.81M | Enterprise value | $62.42M | Trailing P/E | — | Forward P/E | -2.83 |
| PEG | — | Price / book | 16.65 | Beta | 1.61 | Dividend yield | 0.00% |
| Revenue growth | -53.9% | Earnings growth | — | Gross margin | 37.7% | Operating margin | -1.9% |
| Profit margin | -102.8% | ROE | — | ROA | -44.0% | Debt / equity | 0.42 |
| Current ratio | 1.45 | Free cash flow | -$9.04M | Analyst recommendation | strong_buy | Mean target | $13.83 |
| 52w high | $9.82 | 52w low | $3.28 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $5.9M | $5.0M | $5.1M | $14.3M | $12.7M | — |
| Op margin | -194.5% | -193.4% | -136.4% | 11.3% | 11.9% | — |
| Net income | -$13.2M | -$9.7M | -$8.1M | -$0.3M | $0.2M | — |
| Gross margin | 85.0% | 82.3% | 72.5% | 92.3% | 96.1% | — |
| Gross profit | $5.0M | $4.1M | $3.7M | $13.2M | $12.2M | — |
| Operating income | -$11.4M | -$9.7M | -$6.9M | $1.6M | $1.5M | — |
- Revenue +17% vs prior quarter ($5.9M vs $5.0M).
- Gross margin 85% (was 82.3% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M | — |
| Op margin | -33.6% | -870.2% | -1233.8% | -235.8% | — |
| Net income | -$17.9M | -$76.6M | -$67.0M | -$24.5M | — |
| Gross margin | 90.3% | 63.8% | 85.4% | 92.0% | — |
| Gross profit | $32.1M | $4.8M | $4.4M | $8.3M | — |
| Operating income | -$11.9M | -$65.8M | -$63.2M | -$21.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
2026-09-10 · Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
2026-09-08 · Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-28 · Verrica completes enrolment in Phase III trial of Ycanth
2026-08-28 · Lake Street Initiates Verrica Pharmaceuticals at Buy With $9 Price Target
2026-08-07 · Verrica Pharmaceuticals Q2 Earnings Call Highlights
2026-08-06 · Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 · Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
2026-08-06 · Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
2026-07-21 · Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment
Price (daily)
Full chart · RSI · MACD · patterns